psychiatryRounds

Connecting Psychiatry - Expert community for all mental health professionals

(PSYCHIATRIC TIMES) - MedPage Today Action Points

ROCKVILLE, Md., Feb. 22 -- The FDA has ordered all drugs approved for attention deficit hyperactivity disorder to carry guides to inform patients about the potential for cardiovascular risks and adverse psychiatric symptoms.

"Medicines approved for the treatment of ADHD have real benefits for many patients but they may have serious risks as well," said Steven Galson, M.D., director of the FDA's Center for Drug Evaluation and Research.

The guides will be aimed at patients, families, and caregivers, and are to be handed out at pharmacies or in clinics where the drugs are dispensed.

For full article, please visit:
http://www.psychiatrictimes.com/adhd/article/10168/53641

Views: 4

Comment

You need to be a member of psychiatryRounds to add comments!

Join psychiatryRounds


psychiatryRounds Social Media

Sponsors

CMEinfo: Board Reviews in Anesthesia, Cardiology, Internal Medicine, Radiology

© 2019   Created by PsychiatryRounds Team.   Powered by

Badges  |  Report an Issue  |  Terms of Service